FindTrial
Sign In

tracking the safety and value of cancer drugs in a specialised hospital

Pharmacovigilance and Pharmacoeconomics of cancer chemotherapy medications in a tertiary care hospital. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/096700
Enrollment
140
Registered
2025-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Datta Meghe Institute of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cancer patients on chemotherapy treatment 2. Patients with solid tumors or hematological malignancy

Exclusion criteria

Exclusion criteria: 1. Patient not consenting for study 2. Patients on Radiation Therapy

Design outcomes

Primary

MeasureTime frame
Adverse Drug Reaction, Drug Interaction, cost effectiveness, cost utility and budget impact of chemotherapeutic medicationTimepoint: Assessment will be done at two weeks—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Swanad S Pathak

Datta Meghe Institute of Higher Education and Research

swanandspathak@yahoo.com9420529850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026